{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:28:51Z","timestamp":1790436531266,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81472402"],"award-info":[{"award-number":["81472402"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570176"],"award-info":[{"award-number":["81570176"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570180"],"award-info":[{"award-number":["81570180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.prp.2020.152874","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T02:27:37Z","timestamp":1581560857000},"page":"152874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets"],"prefix":"10.1016","volume":"216","author":[{"given":"Kangjie","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linni","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangping","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.prp.2020.152874_bib0005","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-10-1533","article-title":"Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study","volume":"16","author":"O\u2019Brien","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 6","key":"10.1016\/j.prp.2020.152874_bib0010","doi-asserted-by":"crossref","first-page":"vi19","DOI":"10.1093\/annonc\/mds190","article-title":"Pathological and molecular diagnosis of triple-negative breast cancer: a clinical perspective","volume":"23","author":"Penault-Llorca","year":"2012","journal-title":"Ann. Oncol."},{"issue":"16","key":"10.1016\/j.prp.2020.152874_bib0015","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1002\/cncr.25961","article-title":"Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity","volume":"117","author":"Lara-Medina","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.prp.2020.152874_bib0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4196\/kjpp.2013.17.4.291","article-title":"Mutant p53-Notch1 signaling axis Is involved in curcumin-induced apoptosis of breast cancer cells","volume":"17","author":"Bae","year":"2013","journal-title":"Korean J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0025","first-page":"EC05","article-title":"Clinicopathological features of triple negative breast carcinoma","volume":"11","author":"Reddy","year":"2017","journal-title":"J. Clin. Diagn. Res."},{"issue":"7418","key":"10.1016\/j.prp.2020.152874_bib0030","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.prp.2020.152874_bib0035","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2011.03.006","article-title":"Genomic analysis: toward a new approach in breast cancer management","volume":"81","author":"Cavallaro","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0045","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4161\/epi.6.5.15667","article-title":"CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal\/triple-negative breast cancer","volume":"6","author":"Stefansson","year":"2011","journal-title":"Epigenetics"},{"issue":"15","key":"10.1016\/j.prp.2020.152874_bib0050","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/sj.onc.1210295","article-title":"Reactivation of mutant p53: molecular mechanisms and therapeutic potential","volume":"26","author":"Selivanova","year":"2007","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.critrevonc.2013.05.003","article-title":"P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency","volume":"88","author":"Shapira","year":"2013","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.prp.2020.152874_bib0060","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.cell.2009.11.026","article-title":"Mutant p53 drives invasion by promoting integrin recycling","volume":"139","author":"Muller","year":"2009","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.prp.2020.152874_bib0065","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1073\/pnas.97.8.4174","article-title":"High metastatic potential in mice inheriting a targeted p53 missense mutation","volume":"97","author":"Liu","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0070","doi-asserted-by":"crossref","first-page":"638","DOI":"10.4161\/epi.6.5.15667","article-title":"CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal\/triple-negative breast cancer","volume":"6","author":"Stefansson","year":"2011","journal-title":"Epigenetics"},{"issue":"8","key":"10.1016\/j.prp.2020.152874_bib0075","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1158\/0008-5472.CAN-08-3426","article-title":"High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer","volume":"69","author":"Holstege","year":"2009","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cell.2009.01.039","article-title":"A Mutant-p53\/Smad complex opposes p63 to empower TGFbeta-induced metastasis","volume":"137","author":"Adorno","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0085","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1074\/jbc.M504175200","article-title":"rab7 activity affects epidermal growth factor:epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome","volume":"281","author":"Ceresa","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.prp.2020.152874_bib0090","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/sj.onc.1210311","article-title":"Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?","volume":"26","author":"Li","year":"2007","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0095","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2011.06.025","article-title":"Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition","volume":"146","author":"von Kleist","year":"2011","journal-title":"Cell"},{"issue":"7418","key":"10.1016\/j.prp.2020.152874_bib0100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.prp.2020.152874_bib0105","doi-asserted-by":"crossref","first-page":"e78641","DOI":"10.1371\/journal.pone.0078641","article-title":"RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs","volume":"8","author":"Robinson","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.prp.2020.152874_bib0110","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4161\/rna.20481","article-title":"The hallmarks of cancer: a long non-coding RNA point of view","volume":"9","author":"Gutschner","year":"2012","journal-title":"RNA Biol."},{"issue":"2\u20133","key":"10.1016\/j.prp.2020.152874_bib0115","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10142-016-0524-x","article-title":"Long noncoding RNA (lincRNA), a new paradigm in gene expression control","volume":"17","author":"Deniz","year":"2017","journal-title":"Funct. Integr. Genomics"},{"issue":"4","key":"10.1016\/j.prp.2020.152874_bib0120","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3892\/ijo.2013.2059","article-title":"From microRNA functions to microRNA therapeutics: novel targets and novel drugs in breast cancer research and treatment (review)","volume":"43","author":"Piva","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"10","key":"10.1016\/j.prp.2020.152874_bib0125","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.7150\/thno.11543","article-title":"MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction and therapeutic tools for breast cancer","volume":"5","author":"Bertoli","year":"2015","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3892\/or.2016.4767","article-title":"miR-136 suppresses tumor invasion and metastasis by targeting RASAL2 in triple-negative breast cancer","volume":"36","author":"Yan","year":"2016","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010194","article-title":"Integrated MicroRNA-mRNA profiling identifies oncostatin m as a marker of mesenchymal-like ER-negative\/HER2-negative breast cancer","volume":"18","author":"Bottai","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2020.152874_bib0140","first-page":"2639","article-title":"miR-125b inhibited epithelial-mesenchymal transition of triple-negative breast cancer by targeting MAP2K7","volume":"9","author":"Hong","year":"2016","journal-title":"Onco. Ther."},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0145","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3892\/ijo.2015.2821","article-title":"Identification of dysregulated microRNAs in triple-negative breast cancer (review)","volume":"46","author":"Yang","year":"2015","journal-title":"Int. J. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0150","doi-asserted-by":"crossref","first-page":"507","DOI":"10.4161\/cc.10.3.14754","article-title":"MicroRNA expression analysis in triple-negative (ER, PR and Her2\/neu) breast cancer","volume":"10","author":"Radojicic","year":"2011","journal-title":"Cell Cycle"},{"issue":"4","key":"10.1016\/j.prp.2020.152874_bib0155","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.5301\/jbm.5000160","article-title":"High expression levels of miR-21 and miR-210 predict unfavorable survival in breast cancer: a systemic review and meta-analysis","volume":"30","author":"Tang","year":"2015","journal-title":"Int. J. Biol. Markers"},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0160","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.gene.2012.07.025","article-title":"High expression of miR-210 predicts poor survival in patients with breast cancer: a meta-analysis","volume":"507","author":"Hong","year":"2012","journal-title":"Gene"},{"issue":"20","key":"10.1016\/j.prp.2020.152874_bib0165","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.4161\/cc.7.20.6851","article-title":"MicroRNAs as regulators of epithelial-mesenchymal transition","volume":"7","author":"Gregory","year":"2008","journal-title":"Cell Cycle"},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0170","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.cell.2009.07.011","article-title":"Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells","volume":"138","author":"Shimono","year":"2009","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0175","first-page":"311","article-title":"MicroRNAome genome: a treasure for cancer diagnosis and therapy","volume":"64","author":"Berindan-Neagoe","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.prp.2020.152874_bib0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-10-5203-3_1","article-title":"History, discovery, and classification of lncRNAs","volume":"1008","author":"arroux","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrm.2017.104","article-title":"The functions and unique features of long intergenic non-coding RNA","volume":"19","author":"Ransohoff","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.prp.2020.152874_bib0190","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.1002\/jcp.26311","article-title":"Long non-coding RNA (LncRNA) RMST in triple-negative breast cancer (TNBC): expression analysis and biological roles research","volume":"233","author":"Wang","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"8","key":"10.1016\/j.prp.2020.152874_bib0195","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1158\/0008-5472.CAN-15-3284","article-title":"Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value","volume":"76","author":"Jiang","year":"2016","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.prp.2020.152874_bib0200","first-page":"6971","article-title":"Long non-coding RNA FGF14-AS2 represses proliferation, migration, invasion, and induces apoptosis in breast cancer by sponging miR-205-5p","volume":"23","author":"Yang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0205","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/ncb3295","article-title":"The LINK-A lncRNA activates normoxic HIF1alpha signalling in triple-negative breast cancer","volume":"18","author":"Lin","year":"2016","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0210","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9030021","article-title":"In breast Cancer","volume":"9","author":"Rahim","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0215","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s10549-016-3807-y","article-title":"Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer","volume":"157","author":"Thakkar","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"11","key":"10.1016\/j.prp.2020.152874_bib0220","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1158\/1541-7786.MCR-18-1194","article-title":"STAT3 targets ERR-alpha to promote epithelial-mesenchymal transition, migration, and invasion in triple-negative breast cancer cells","volume":"17","author":"Ma","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"28","key":"10.1016\/j.prp.2020.152874_bib0225","doi-asserted-by":"crossref","first-page":"25588","DOI":"10.18632\/oncotarget.4436","article-title":"Inhibition of ERRalpha suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2020.152874_bib0230","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/OTT.S67673","article-title":"Triple-negative breast cancer: new perspectives for targeted therapies","volume":"8","author":"Tomao","year":"2015","journal-title":"Onco. Ther."},{"issue":"4","key":"10.1016\/j.prp.2020.152874_bib0235","first-page":"687","article-title":"A novel class of substituted spiro [quinazoline-2,1\u2019-cyclohexane] derivatives as effective PPAR-1 inhibitors: molecular modeling, synthesis, cytotoxic and enzyme assay evaluation","volume":"70","author":"Amin","year":"2013","journal-title":"Acta Pol. Pharm."},{"key":"10.1016\/j.prp.2020.152874_bib0240","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ctrv.2017.11.003","article-title":"Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies","volume":"62","author":"Lee","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.prp.2020.152874_bib0245","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13053-019-0111-y","article-title":"The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis","volume":"17","author":"Caramelo","year":"2019","journal-title":"Hered. Cancer Clin. Pract."},{"issue":"4","key":"10.1016\/j.prp.2020.152874_bib0250","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1535-7163.MCT-14-0474","article-title":"Efficacy of carboplatin alone and in combination with ABT888 in intracranial murine models of BRCA-mutated and BRCA-wild-type triple-negative breast cancer","volume":"14","author":"Karginova","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0255","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1038\/s41598-017-07617-7","article-title":"H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer","volume":"7","author":"Mazzucchelli","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0260","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10549-016-3746-7","article-title":"Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer","volume":"156","author":"Rangel","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0265","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1158\/0008-5472.CAN-06-3958","article-title":"Notch signaling, gamma-secretase inhibitors, and cancer therapy","volume":"67","author":"Shih","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0270","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1066896911427035","article-title":"Notch-1 and Notch-4 biomarker expression in triple-negative breast cancer","volume":"20","author":"Speiser","year":"2012","journal-title":"Int. J. Surg. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0275","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/hep.27268","article-title":"Emerging roles of Notch signaling in liver disease","volume":"61","author":"Geisler","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.prp.2020.152874_bib0280","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/B978-0-12-416673-8.00013-7","article-title":"The functional role of Notch signaling in triple-negative breast cancer","volume":"93","author":"Speiser","year":"2013","journal-title":"Vitam. Horm."},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0285","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10549-016-3746-7","article-title":"Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer","volume":"156","author":"Rangel","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2020.152874_bib0290","first-page":"943","article-title":"Gamma secretase inhibitors of Notch signaling","volume":"6","author":"Olsauskas-Kuprys","year":"2013","journal-title":"Onco. Ther."},{"issue":"4","key":"10.1016\/j.prp.2020.152874_bib0295","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/1940-6207.CAPR-14-0257","article-title":"Notch1 mutations are drivers of oral tumorigenesis","volume":"8","author":"Izumchenko","year":"2015","journal-title":"Cancer Prev. Res. (Phila)"},{"issue":"6","key":"10.1016\/j.prp.2020.152874_bib0300","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1158\/1078-0432.CCR-14-1348","article-title":"PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a gamma-secretase inhibitor","volume":"21","author":"Wang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2020.152874_bib0305","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3389\/fonc.2018.00575","article-title":"Notch signaling regulates mitochondrial metabolism and NF-kappaB activity in triple-negative breast cancer cells via IKKalpha-dependent non-canonical pathways","volume":"8","author":"Hossain","year":"2018","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.prp.2020.152874_bib0310","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nrd2154","article-title":"Mining the Wnt pathway for cancer therapeutics","volume":"5","author":"Barker","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0315","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0320","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4161\/cbt.9.1.10392","article-title":"Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer","volume":"9","author":"Bayet-Robert","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0325","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcb.23350","article-title":"The Wnt\/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer","volume":"113","author":"King","year":"2012","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.prp.2020.152874_bib0330","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.25956","article-title":"Role of wnt Co-receptor LRP6 in triple negative breast cancer cell migration and invasion","author":"Ma","year":"2017","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0335","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.gde.2006.12.007","article-title":"The many ways of Wnt in cancer","volume":"17","author":"Polakis","year":"2007","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"4","key":"10.1016\/j.prp.2020.152874_bib0340","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.cellsig.2011.12.009","article-title":"Frizzled7 as an emerging target for cancer therapy","volume":"24","author":"King","year":"2012","journal-title":"Cell. Signal."},{"issue":"40","key":"10.1016\/j.prp.2020.152874_bib0345","doi-asserted-by":"crossref","first-page":"43016","DOI":"10.18632\/oncotarget.5513","article-title":"Inhibition of the Tcf\/beta-catenin complex increases apoptosis and impairs adrenocortical tumor cell proliferation and adrenal steroidogenesis","volume":"6","author":"Leal","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.prp.2020.152874_bib0350","doi-asserted-by":"crossref","first-page":"e29290","DOI":"10.1371\/journal.pone.0029290","article-title":"Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt\/beta-catenin pathway","volume":"6","author":"Lu","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0355","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2184.2008.00581.x","article-title":"Silymarin inhibited proliferation and induced apoptosis in hepatic cancer cells","volume":"42","author":"Ramakrishnan","year":"2009","journal-title":"Cell Prolif."},{"issue":"7","key":"10.1016\/j.prp.2020.152874_bib0360","doi-asserted-by":"crossref","first-page":"e23000","DOI":"10.1371\/journal.pone.0023000","article-title":"Silymarin targets beta-catenin signaling in blocking migration\/invasion of human melanoma cells","volume":"6","author":"Vaid","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0365","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1593\/neo.10188","article-title":"Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling","volume":"12","author":"Kaur","year":"2010","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.prp.2020.152874_bib0370","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.cellsig.2012.07.009","article-title":"Silibinin inhibits Wnt\/beta-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells","volume":"24","author":"Lu","year":"2012","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0375","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1535-6108(03)00334-9","article-title":"Small-molecule antagonists of the oncogenic Tcf\/beta-catenin protein complex","volume":"5","author":"Lepourcelet","year":"2004","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.prp.2020.152874_bib0380","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/ijc.24810","article-title":"Small molecule antagonists of Tcf4\/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo","volume":"126","author":"Wei","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.prp.2020.152874_bib0385","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/nrd2154","article-title":"Mining the Wnt pathway for cancer therapeutics","volume":"5","author":"Barker","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.prp.2020.152874_bib0390","doi-asserted-by":"crossref","first-page":"e29290","DOI":"10.1371\/journal.pone.0029290","article-title":"Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt\/beta-catenin pathway","volume":"6","author":"Lu","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0395","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.devcel.2015.05.016","article-title":"Deubiquitination of Ci\/Gli by Usp7\/HAUSP regulates hedgehog signaling","volume":"34","author":"Zhou","year":"2015","journal-title":"Dev. Cell"},{"issue":"10","key":"10.1016\/j.prp.2020.152874_bib0400","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1002\/cam4.833","article-title":"The hedgehog pathway in triple-negative breast cancer","volume":"5","author":"Habib","year":"2016","journal-title":"Cancer Med."},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0405","first-page":"995","article-title":"Overexpression of Hedgehog signaling molecules and its involvement in triple-negative breast cancer","volume":"2","author":"Tao","year":"2011","journal-title":"Oncol. Lett."},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0410","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/ncponc0794","article-title":"Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification","volume":"4","author":"Polkinghorn","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0415","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/1758834016653605","article-title":"Hedgehog pathway inhibition in advanced basal cell carcinoma: latest evidence and clinical usefulness","volume":"8","author":"Silapunt","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.prp.2020.152874_bib0420","first-page":"1","article-title":"Ursolic acid derivative FZU-03,010 inhibits STAT3 and induces cell cycle arrest and apoptosis in renal and breast cancer cells","author":"Li","year":"2017","journal-title":"Acta Biochim. Biophys. Sin. (Shanghai)"},{"key":"10.1016\/j.prp.2020.152874_bib0425","article-title":"(-)-Epicatechin induces physiological cardiac growth by activation of the pi3k\/akt pathway in mice","author":"De Los","year":"2016","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.prp.2020.152874_bib0430","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.10858","article-title":"Triple negative breast cancer: shedding light onto the role of pi3k\/akt\/mtor pathway","author":"Massihnia","year":"2016","journal-title":"Oncotarget"},{"issue":"7418","key":"10.1016\/j.prp.2020.152874_bib0435","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0440","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.breast.2011.09.008","article-title":"mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors","volume":"21","author":"Walsh","year":"2012","journal-title":"Breast"},{"issue":"4","key":"10.1016\/j.prp.2020.152874_bib0445","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/1758834014530023","article-title":"The PI3K\/AKT\/mTOR pathway in breast cancer: targets, trials and biomarkers","volume":"6","author":"Paplomata","year":"2014","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0450","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ijc.24831","article-title":"PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality","volume":"126","author":"Lopez-Knowles","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0455","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno","year":"2004","journal-title":"Cancer Treat. Rev."},{"issue":"12","key":"10.1016\/j.prp.2020.152874_bib0460","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1128\/MCB.21.12.3995-4004.2001","article-title":"HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression","volume":"21","author":"Laughner","year":"2001","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0465","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"mTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0470","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbapap.2009.12.001","article-title":"Dissecting the role of mTOR: lessons from mTOR inhibitors","volume":"1804","author":"Dowling","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0475","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canlet.2012.01.015","article-title":"Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition","volume":"319","author":"Kimbung","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2020.152874_bib0480","first-page":"43","article-title":"Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes","volume":"6","author":"Jerusalem","year":"2014","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"23","key":"10.1016\/j.prp.2020.152874_bib0485","doi-asserted-by":"crossref","first-page":"34038","DOI":"10.18632\/oncotarget.8697","article-title":"Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain","volume":"7","author":"Wan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2020.152874_bib0490","doi-asserted-by":"crossref","DOI":"10.1007\/s11356-017-8773-3","article-title":"Genome-wide transcriptional analysis of cardiovascular-related genes and pathways induced by PM2.5 in human myocardial cells","author":"Feng","year":"2017","journal-title":"Environ. Sci. Pollut. Res. Int."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0495","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cyto.2015.05.020","article-title":"Elevated TGF-beta1 and -beta2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells","volume":"75","author":"Kim","year":"2015","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.prp.2020.152874_bib0500","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.3892\/ol.2016.4497","article-title":"Association between transforming growth factor-beta1 expression and the clinical features of triple negative breast cancer","volume":"11","author":"Ding","year":"2016","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2020.152874_bib0505","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1600-065X.2006.00437.x","article-title":"TGF-beta: a mobile purveyor of immune privilege","volume":"213","author":"Wahl","year":"2006","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0510","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3892\/mmr.2015.3560","article-title":"Transforming growth factor-beta, insulin-like growth factor I\/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer","volume":"12","author":"Bahhnassy","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0515","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1172\/JCI65416","article-title":"TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer","volume":"123","author":"Bhola","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.prp.2020.152874_bib0520","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5152\/tjbh.2014.1904","article-title":"The outcome of patients with triple negative breast cancer: the turkish oncology group experience","volume":"10","author":"Eralp","year":"2014","journal-title":"J. Breast Health (2013)"},{"issue":"8","key":"10.1016\/j.prp.2020.152874_bib0525","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI32278","article-title":"ErbB receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"Zhang","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.prp.2020.152874_bib0530","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0974-2727.163129","article-title":"Epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas","volume":"7","author":"Changavi","year":"2015","journal-title":"J. Lab. Physicians"},{"key":"10.1016\/j.prp.2020.152874_bib0535","doi-asserted-by":"crossref","DOI":"10.1038\/msb4100030","article-title":"The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation","volume":"1","author":"Tabach","year":"2005","journal-title":"Mol. Syst. Biol."},{"issue":"1\u20134","key":"10.1016\/j.prp.2020.152874_bib0540","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.anireprosci.2011.03.002","article-title":"Activation of PI3K\/mTOR signaling pathway contributes to induction of vascular endothelial growth factor by hCG in bovine developing luteal cells","volume":"125","author":"Zhang","year":"2011","journal-title":"Anim. Reprod. Sci."},{"key":"10.1016\/j.prp.2020.152874_bib0545","doi-asserted-by":"crossref","first-page":"324","DOI":"10.7150\/jca.2.324","article-title":"Targeting EGFR in triple negative breast cancer","volume":"2","author":"Ueno","year":"2011","journal-title":"J. Cancer"},{"issue":"15","key":"10.1016\/j.prp.2020.152874_bib0550","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1158\/0008-5472.CAN-09-0049","article-title":"Cetuximab\/C225-induced intracellular trafficking of epidermal growth factor receptor","volume":"69","author":"Liao","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.prp.2020.152874_bib0555","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tcb.2008.03.004","article-title":"Endocytic transport of integrins during cell migration and invasion","volume":"18","author":"Caswell","year":"2008","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.prp.2020.152874_bib0560","article-title":"E3 ubiquitin ligase UBR5 drives the growth and metastasis of triple negative breast cancer","author":"Liao","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2020.152874_bib0565","doi-asserted-by":"crossref","DOI":"10.1007\/s10549-017-4201-0","article-title":"Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression","author":"Strekalova","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.prp.2020.152874_bib0570","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejmech.2017.03.006","article-title":"New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo","volume":"131","author":"Hsieh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.prp.2020.152874_bib0575","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1159\/000494874","article-title":"Targeting thioredoxin system with an organosulfur compound, Diallyl Trisulfide (DATS), attenuates progression and metastasis of triple-negative breast cancer (TNBC)","volume":"50","author":"Liu","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0580","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13058-016-0749-6","article-title":"PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells","volume":"18","author":"Byerly","year":"2016","journal-title":"Breast Cancer Res."},{"issue":"Pt 10","key":"10.1016\/j.prp.2020.152874_bib0585","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1242\/jcs.062661","article-title":"MUC1 regulates nuclear localization and function of the epidermal growth factor receptor","volume":"123","author":"Bitler","year":"2010","journal-title":"J. Cell. Sci."},{"issue":"22","key":"10.1016\/j.prp.2020.152874_bib0590","doi-asserted-by":"crossref","first-page":"32796","DOI":"10.18632\/oncotarget.8743","article-title":"MUC1 stimulates EGFR expression and function in endometrial cancer","volume":"7","author":"Engel","year":"2016","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.prp.2020.152874_bib0595","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/onc.2012.158","article-title":"MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches","volume":"32","author":"Kufe","year":"2013","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.prp.2020.152874_bib0600","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.humpath.2013.04.010","article-title":"MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer","volume":"44","author":"Siroy","year":"2013","journal-title":"Hum. Pathol."},{"issue":"1","key":"10.1016\/j.prp.2020.152874_bib0605","doi-asserted-by":"crossref","first-page":"e0145920","DOI":"10.1371\/journal.pone.0145920","article-title":"MUC1 vaccines, comprised of glycosylated or non-glycosylated peptides or tumor-derived MUC1, can circumvent immunoediting to control tumor growth in MUC1 transgenic mice","volume":"11","author":"Lakshminarayanan","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.prp.2020.152874_bib0610","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.31272","article-title":"Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here","volume":"124","author":"Kwa","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.prp.2020.152874_bib0615","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nrclinonc.2017.101","article-title":"The immune contexture in cancer prognosis and treatment","volume":"14","author":"Fridman","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2020.152874_bib0620","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/annonc\/mdy517","article-title":"Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study","volume":"30","author":"Adams","year":"2019","journal-title":"Ann. Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403381931831X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403381931831X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:42:03Z","timestamp":1759732923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S034403381931831X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":124,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S034403381931831X"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2020.152874","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in triple negative breast carcinoma pathophysiology: Potential therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2020.152874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152874"}}